Sign in

CIK 0001393434

  • Large accelerated filer

OCULAR THERAPEUTIX, INC

Sign in to watch
Ticker
OCUL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 781-357-4000
Business address
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730
Former names
I-THERAPEUTIX INC
  1. 4 Grant or award Chief Legal Officer acquired 64,900 shares (grant or award)
  2. 4 Grant or award Chief Commercial Officer acquired 64,900 shares (grant or award)
  3. 4 Grant or award Chief Strategy Officer acquired 64,900 shares (grant or award)
  4. 4 Grant or award Chief Development Officer acquired 79,112 shares (grant or award)
  5. 4 Grant or award Chief Business Officer acquired 79,112 shares (grant or award)
  6. 4 Grant or award Chief Medical Officer acquired 79,112 shares (grant or award)
  7. 4 Grant or award Chief Scientific Officer acquired 79,112 shares (grant or award)
  8. 4 Grant or award See Remarks acquired 79,112 shares (grant or award)
  9. 4 Planned sale Chief Strategy Officer sold 1,878 shares at $12.04 ($22,611)
  10. 4 Planned sale See Remarks sold 19,530 shares at $12.04 ($235,141)
  11. 4 Planned sale Chief Development Officer sold 3,007 shares at $12.02 ($36,144)
  12. 4 Planned sale Chief Scientific Officer sold 3,469 shares at $12.04 ($41,767)
  13. 4 Planned sale Chief Business Officer sold 25,865 shares at $10.74 ($277,790)
  14. 4 Planned sale Chief Legal Officer sold 11,132 shares at $12.34 ($137,369)
  15. 4 Planned sale Chief Development Officer sold 9,653 shares at $11.03 ($106,473)
  16. 4 Planned sale Chief Scientific Officer sold 10,502 shares at $11.04 ($115,942)
  17. 4 Gift See Remarks gave 49,754 shares (gift)
  18. 4 Open-market sale See Remarks sold 1,066 shares at $12.43 ($13,250)
  19. 4 Planned sale Chief Development Officer sold 3,011 shares at $12.04 ($36,252)
  20. 4 Planned sale Chief Strategy Officer sold 1,885 shares at $12.04 ($22,695)

Page 3 of 18 · 354 filings